News | 08 August 2023
Surging demand for Korean pharma in 2023 ahead of CPHI Korea
Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings
Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings
The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023
Fortis Healthcare has reported total income of Rs. 1665.55 crores during the period ended June 30, 2023
The company has reported total income of Rs. 310.07 crores during the period ended June 30, 2023
The company has reported total income of Rs. 704.5 crores during the period ended June 30, 2023
The company has posted net profit of Rs. 463.88 crores for the period ended June 30, 2023
The company has reported total income of Rs. 4836.89 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1787.16 crores during the period ended June 30, 2023
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
The company has reported total income of Rs. 62.15 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1248.51 crores during the period ended June 30, 2023
Medica Superspecialty Hospital becomes the first private hospital in Eastern India to collaborate with UNICEF for breastfeeding workshop
Qualicaps is the third largest producer of hard capsules for oral dosage solutions
With an annual revenue of about $500 million, Spectrum will become part of the Industrial Solutions line of business within the Electronics & Industrial segment
The company has reported total income of Rs. 135.87 crores during the period ended June 30, 2023
The company has reported total income of Rs. 164.63 crores during the period ended June 30, 2023
The company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
The company has secured 506 marketing approvals for its oncology products across 76 countries.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Subscribe To Our Newsletter & Stay Updated
